David Kimble, MD
Urogynecology and Reconstructive Pelvic Surgery · Pasadena, CANPI 1447244868
Payments from drug & device makers
What this record shows
This record is dominated by education: $7,285 of the $10,946 with a category attached, or 66.6%. Coloplast accounts for 78.2% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $8,424 and has fallen 79.5% since, to $1,727 in 2025.
Across 48 payments — averaging $228.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$9K
- Biotissue Holdings Inc.$2K
- Caldera Medical, Inc$525
- AbbVie$97
- Boston Scientific$63
- Axonics, Inc.$57
- plus $74 from 3 others
What the payments were for
- Travel & lodging$1,95318%
- Food & beverage$1,64615%
- Education$7,28567%
- Gifts$611%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 15 | $8,556 |
| Biotissue Holdings Inc. | 9 | $1,574 |
| Caldera Medical, Inc | 12 | $525 |
| AbbVie | 4 | $97 |
| Boston Scientific | 3 | $63 |
| Axonics, Inc. | 2 | $57 |
| Hologic Sales And Service, LLC | 1 | $31 |
| Bayer | 1 | $23 |
| Medline Industries LP | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,946 in reported general payments places this provider in the 75th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
See all urogynecology and reconstructive pelvic surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 38 | $21,051 |
| Estradiol | 15 | $1,048 |
| Oxybutynin Chloride ErOxybutynin Chloride | 34 | $667 |
| Solifenacin Succinate | 15 | $657 |
| Tolterodine Tartrate ErTolterodine Tartrate | 11 | $519 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 32 | $170 |
| Ibuprofen | 19 | $84 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 15 | $67 |
Paid to pharmacies, not to this prescriber.
Other urogynecology and reconstructive pelvic surgery in Pasadena
- Andrew BrillSan Francisco$345K
- Bilal KaakiRiverside$301K
- Savitha KrishnanMountain View$243K
- Peter CastilloLos Gatos$95K
- Bruce Kahnla Jolla$79K
- Jennifer GruenenfelderOrange$76K
- Traci ItoSan Francisco$68K
- Tanaz FerzandiLos Angeles$60K
- Sadikah BehbehaniCosta Mesa$53K
- Christopher TarnayLos Angeles$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.